Press Releases May 5, 2026 07:00 AM

FactSet Increases Dividend

FactSet Raises Quarterly Dividend for the 27th Consecutive Year to Reward Shareholders

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
FDS

FactSet's Board of Directors announced an increase in the quarterly dividend from $1.10 to $1.16 per share, continuing its long-standing commitment to shareholder returns. This marks the 27th consecutive year of dividend increases on a stock split-adjusted basis, highlighting the company's strong financial performance and stability. The dividend will be paid on June 18, 2026, to shareholders of record as of May 29, 2026.

FactSet Increases Dividend
FDS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • FactSet increased its quarterly dividend by $0.06 to $1.16 per share, reflecting sustained profitability and shareholder commitment.
  • This marks 27 consecutive years of dividend growth, underscoring FactSet's financial stability and consistent performance.
  • FactSet continues to serve over 9,000 global clients with cutting-edge financial data solutions integrating AI and next-generation tools, supporting sectors such as financial services, wealth management, private equity, and corporate finance.

NORWALK, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- FactSet (NYSE: FDS | NASDAQ: FDS), a global financial digital platform and enterprise solutions provider, today announced that its Board of Directors approved an increase in the regular quarterly cash dividend to $1.16 per share from $1.10 per share.

The $0.06 per share increase marks the twenty-seventh consecutive year the Company has increased dividends on a stock split-adjusted basis, demonstrating its ongoing commitment to providing value to shareholders. The cash dividend will be paid on June 18, 2026, to holders of record of FactSet’s common stock at the close of business on May 29, 2026.

About FactSet

FactSet (NYSE:FDS | NASDAQ:FDS) supercharges financial intelligence, offering enterprise data and information solutions that power our clients to maximize their potential. Our cutting-edge digital platform seamlessly integrates proprietary financial data, client datasets, third-party sources, and flexible technology to deliver tailored solutions across the buy-side, sell-side, wealth management, private equity, and corporate sectors. With over 47 years of expertise, offices in 19 countries, and extensive multi-asset class coverage, we leverage advanced data connectivity alongside AI and next-generation tools to streamline workflows, drive productivity, and enable smarter, faster decision-making. Serving more than 9,000 global clients and over 241,000 individual users, FactSet is a member of the S&P 500 dedicated to innovation and long-term client success. Learn more at www.factset.com and follow us on X and LinkedIn.

FactSet
Investor Relations:
Kevin Toomey
+1.212.209.5259
Kevin.toomey@factset.com

Media Relations:
Vested
+1.917.291.2366
Factset@fullyvested.com


Risks

  • The company's continued dividend growth depends on maintaining strong financial performance amid competitive pressures in the financial data and analytics sector.
  • Economic downturns or disruptions could impact client demand for enterprise data and analytic solutions, potentially affecting future cash flow and dividend payments.
  • Technological changes and the need to continuously innovate with AI and other tools pose execution risks that may affect long-term growth prospects and market positioning.

More from Press Releases

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress Jun 14, 2026 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026